SCHEMBL2978719

SCHEMBL2978719

COc1cccc(Cl)c1-c1cncc(C#N)c1Nc1ccc2[nH]ccc2c1C

nearest known ligand 0.76

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 20/20 0.76
PRKCD Q05655 20/20 0.76
LYN P07948 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2972934 0.86 PRKCQ (1.00) PRKCQPRKCDLYN
SCHEMBL2986068 0.84 PRKCQ (0.71) PRKCQPRKCD
SCHEMBL2980060 0.81 PRKCQ (0.75) PRKCQPRKCD
SCHEMBL2979788 0.81 PRKCQ (0.77) PRKCQPRKCD
SCHEMBL2980087 0.81 PRKCQ (1.00) PRKCQPRKCD
SCHEMBL2984059 0.80 PRKCQ (0.76) PRKCQPRKCDLYN
SCHEMBL2984688 0.80 PRKCQ (1.00) PRKCQPRKCD
SCHEMBL2982097 0.80 PRKCQ (1.00) PRKCQPRKCD
SCHEMBL2932633 0.79 PRKCQ (1.00) PRKCQPRKCDLYN
SCHEMBL2932635 0.79 PRKCQ (1.00) PRKCQPRKCDLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029543-B1 SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS WYETH LLC (US) 2015-11-18 EP claimed
US-7781591-B2 Substituted 3-cyanopyridines as protein kinase inhibitors WYETH LLC (US) 2010-08-24 US claimed
US-20070287708-A1 Substituted 3-cyanopyridines as protein kinase inhibitors WYETH LLC 2007-12-13 US claimed
EP-2029543-B1 SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS WYETH LLC (US) 2015-11-18 EP disclosed
US-7781591-B2 Substituted 3-cyanopyridines as protein kinase inhibitors WYETH LLC (US) 2010-08-24 US disclosed
US-20070287708-A1 Substituted 3-cyanopyridines as protein kinase inhibitors WYETH LLC 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287708-A1 Substituted 3-cyanopyridines as protein kinase inhibitors CNKSR1, MAP3K1, MAP3K7 PRKCQ 165/4885PRKCD 323/4885LYN 251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.